The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)1

Nothing less than the opportunity
to reach for their treatment goals

For your patients,
that’s everything.

WELL-STUDIED SAFETY PROFILE

EFFICACY IN PsA DOMAINS

WELL-STUDIED SAFETY PROFILE

Evaluated in 24 clinical trials (4 PsA, 20 Ps)2*

 

Up to ~8 years of safety data in Ps, ~3 years in PsA2

 

The safety profile in PsA is generally consistent with the safety profile of patients with Ps (PsA Week 24, Ps Week 16)1

EFFICACY IN PsA DOMAINS

Robust Joint Efficacy: SKYRIZI met its primary endpoint (ACR20 at Week 24) in 2 clinical trials.1 ACR50/70, complete resolution of enthesitis/dactylitis, and minimal disease activity were achieved at Week 24. Response rates observed up to ~2 years in PsA1,3,4,6

Durable Skin Clearance: PASI 90 response was achieved at Week 24. Response rates observed up to ~2 years3,4,6

EXCEPTIONAL ACCESS & SUPPORT

>95% preferred commercial and Medicare Part D first-line TIM coverage with no requirements of a prior biologic.5‡

National Commercial and Medicare Part D Formulary coverage under the pharmacy benefit as of April 2023.5

Skyrizi Complete provides exceptional 1:1 patient support

*Includes 4 PsA Phase 2-3 studies (including KEEPsAKE 1 and KEEPsAKE 2). Includes 20 Phase 1-4 studies in Ps encompassing 5 trials using integrated data evaluated at Week 16 (including UltlMMa-1, UltlMMa-2, IMMhance, and IMMvent), and 15 additional trials including LIMMitless.2

SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

 

ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 other core criteria; ACR50=improvement of at least 50% in tender joint count, swollen joint count, and at least 3 other core criteria; ACR70=improvement of at least 70% in tender joint count, swollen joint count, and at least 3 other core criteria; PASI 90=≥90% improvement in Psoriasis Area and Severity Index; TIM=targeted immunomodulator.

ACR20 Achieved At Week 241,4,6

KEEPsAKE 1:

ACR20

Week 24 (primary endpoint)§:

57%

SKYRIZI
n=483

VS

34%

PLACEBO
n=224

KEEPsAKE 2:

ACR20

Week 24 (primary endpoint)§:

51%

SKYRIZI
n=224

VS

27%

PLACEBO
n=219

ACR50

Week 24 (non-ranked secondary endpoint)||:

33%

SKYRIZI
n=483

VS

11%

PLACEBO
n=481

ACR50

Week 24 (non-ranked secondary endpoint)||:

26%

SKYRIZI
n=224

VS

9%

PLACEBO
n=219

NRI-C analysis used for Week 24.

§Multiplicity-controlled P≤0.001 SKYRIZI 150 mg vs placebo comparison.

Nominal P≤0.001 SKYRIZI 150 mg vs placebo comparison.

STUDY DESIGN:

KEEPsAKE 1 was a 24-week, randomized, double-blind, placebo-controlled study of 964 csDMARD-IR adult patients with active PsA.1,7

 

KEEPsAKE 2 was a 24-week, randomized, double-blind, placebo-controlled study of 443 mixed-population (~50% csDMARD-IR, ~50% bio-IR) adult patients with active PsA.1,8

NRI-C=non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19.

>95%

PREFERRED COMMERCIAL AND
MEDICARE PART D COVERAGE FOR
PsA5‡

National Commercial and Medicare Part D Formulary coverage under the pharmacy benefit as of April 2023.5

SKYRIZI is on a preferred tier or otherwise has preferred status on the plan's formulary.

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

SKYRIZI® Complete Logo.

NO CHARGE FOR ELIGIBLE, COMMERCIALLY INSURED PATIENTS EXPERIENCING INITIAL INSURANCE DENIAL FOR UP TO 24 MONTHS

Download or email Skyrizi Complete Enrollment and Prescription Form

Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

#1 prescribed biologic by dermatologists for patients with psoriatic disease.

#1 PRESCRIPTION ANALYSIS CALCULATED BY COMBINED PRESCRIPTION DATA ACROSS Ps AND PsA

For patients with psoriatic disease, defined as those with plaque psoriasis or psoriatic arthritis. Source of data: Integrated Symphony Health (PatientSource) as of 8/2022.9

""

4 DOSES PER YEAR1

4-dose-per-year biologic** for PsA & for Ps that offers a single-dose pen

**After Week 0 and Week 4 injections.